Literature DB >> 807629

Immunologic hyporesponsiveness in man to group C meningococcal polysaccharide.

M S Artenstein, B L Brandt.   

Abstract

By using a hemagglutination-inhibition assay, certain lots of purified group A meningococcal polysaccharide vaccines were found to contain trace amounts of group C polysaccharide (0.032 to 0.128%). Young adult human volunteers inoculated with these vaccines showed a very poor group C serum anti-polysaccharide antibody response as determined by a radioactive antigen-binding assay. Two weeks later volunteers were given a 50-mug subcutaneous injection of purified group C polysaccharide. Serum specimens obtained 1 month later showed a significant suppression of group C antibody response in comparison with subjects who had initially received group A vaccines which were free of group C antigen. The observed hyporesponsiveness may represent an example of immunologic tolerance in man.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 807629

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Meningococcal group C conjugate vaccines.

Authors:  J Maclennan
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

2.  Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.

Authors:  Q Zhang; R Lakshman; R Burkinshaw; S Choo; J Everard; S Akhtar; A Finn
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

3.  Effect of rheumatoid factors and normal human sera on immune complex-Fc gamma R interaction.

Authors:  M A Isturiz; M Giordano; G P Serebrinsky
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

4.  Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.

Authors:  M A Julie Westerink; Harry W Schroeder; Moon H Nahm
Journal:  Aging Dis       Date:  2011-07-20       Impact factor: 6.745

Review 5.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Meningococcal vaccines. Current status and future possibilities.

Authors:  H Peltola
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

7.  Delayed-type hypersensitivity responses in infected mice elicited by cytoplasmic fractions of Cryptococcus neoformans.

Authors:  R J Hay; E Reiss
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

8.  Immunological and biochemical studies of meningococcal C polysaccharides isolated by diethylaminoethyl chromatography.

Authors:  M A Apicella
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.